{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:52:41Z","timestamp":1770749561585,"version":"3.50.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Heparin-induced thrombocytopaenia (HIT) is an immune-mediated reaction to heparin therapy that may lead to life-threatening thrombotic events. This disorder complicates intraoperative heparin use during left ventricular assist device (LVAD) implantation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>A 52-year-old man presented in acute decompensated heart failure. His admission laboratory studies were consistent with cardiogenic shock with a lactate of 6.1\u2005mmol\/L (ref range 0.50\u20131.99\u2005mmol\/L). Echocardiogram and CT scan demonstrated severe biventricular dysfunction and a left ventricular ejection fraction of 10%, as well as left upper lobe segmental pulmonary embolism. He was started on inotropes, diuretics, and a heparin infusion. Following heparin initiation, his platelets had decreased by 63% to a nadir of 39 000\/\u00b5L (ref range 150 000\u2013450 000\/\u00b5L) and testing confirmed a diagnosis of HIT. His shock state worsened to INTERMACS 1 necessitating escalation of mechanical support. In preparation for HeartMate 3 LVAD implantation, he received 3 cycles of plasmapheresis with one session of IVIG perioperatively, resulting in a 60% reduction in the titre of heparin-dependent platelet antibodies. He underwent successful LVAD implantation including usage of intraoperative heparin, and was discharged home on post-operative Day 17, where he has remained stable on LVAD support.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Limited data exist on the perioperative management of patients with HIT undergoing LVAD implantation. Heparin is preferred to other antithrombin agents during surgery due to the availability of an immediate reversal agent. Plasmapheresis with IVIG is a potential management option to decrease heparin-dependent platelet antibodies in patients with HIT to allow for successful LVAD implantation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytad496","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T13:44:40Z","timestamp":1696859080000},"source":"Crossref","is-referenced-by-count":3,"title":["Heparin-induced thrombocytopaenia complicating cardiogenic shock requiring durable mechanical circulatory support: a case report"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2138-1493","authenticated-orcid":false,"given":"Peter","family":"Cangialosi","sequence":"first","affiliation":[{"name":"Department of Medicine, Mount Sinai Hospital , 1 Gustave Levy Pl, New York, NY 10029 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3408-3823","authenticated-orcid":false,"given":"Francine","family":"Dembitzer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mount Sinai Hospital , 1 Gustave Levy Pl, New York, NY 10029 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anelechi C","family":"Anyanwu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mount Sinai Hospital , 1 Gustave Levy Pl, New York, NY 10029 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Parikh","sequence":"additional","affiliation":[{"name":"Advanced Heart Failure and Transplant Cardiology, Hospital of the University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"2023102422360271100_ytad496-B1","volume-title":"Heparin induced thrombocytopenia. [Updated 2023 Mar 7]. In: StatPearls [internet]","author":"Nicolas","year":"2023"},{"key":"2023102422360271100_ytad496-B2","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"2023102422360271100_ytad496-B3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jca.20289","article-title":"Use of plasma exchange in patients with heparin-induced thrombocytopenia: a report of two cases and a review of the literature","volume":"26","author":"Jaben","year":"2011","journal-title":"J Clin Apher"},{"key":"2023102422360271100_ytad496-B4","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1016\/j.jtcvs.2010.06.018","article-title":"Novel use of plasmapheresis in a patient with heparin-induced thrombocytopenia requiring urgent insertion of a left ventricular assist device under cardiopulmonary bypass","volume":"140","author":"Voeller","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2023102422360271100_ytad496-B5","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1097\/MAT.0000000000001631","article-title":"Management of heparin-induced thrombocytopenia using plasmapharesis in patients undergoing HeartMate 3 left ventricular assist device","volume":"68","author":"Naqvi","year":"2022","journal-title":"ASAIO J"},{"key":"2023102422360271100_ytad496-B6","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1053\/j.jvca.2021.03.037","article-title":"The triple HIT: perioperative management of heparin-induced thrombocytopenia using plasma exchange, intravenous immunoglobulin, and protamine infusion for left ventricular assist device implantation","volume":"36","author":"Liu","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"2023102422360271100_ytad496-B7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jtcvs.2005.11.012","article-title":"Anticoagulation for cardiopulmonary bypass: is a replacement for heparin on the horizon?","volume":"131","author":"Warkentin","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2023102422360271100_ytad496-B8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.athoracsur.2017.09.061","article-title":"The Society of Thoracic Surgeons, the Society of Cardiovascular Anesthesiologists, and the American Society of ExtraCorporeal Technology: clinical practice guidelines-anticoagulation during cardiopulmonary bypass","volume":"105","author":"Shore-Lesserson","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"2023102422360271100_ytad496-B9","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1111\/trf.16018","article-title":"Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin-induced thrombocytopenia: a systematic review","volume":"60","author":"Onuoha","year":"2020","journal-title":"Transfusion"},{"key":"2023102422360271100_ytad496-B10","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytad496\/51953587\/ytad496.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/7\/10\/ytad496\/52458173\/ytad496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/7\/10\/ytad496\/52458173\/ytad496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T22:36:17Z","timestamp":1698186977000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytad496\/7300977"}},"subtitle":[],"editor":[{"given":"Diego","family":"Araiza-Garaygordobil","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Michelle","family":"Feijen","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Christophe","family":"Vandenbriele","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Marta","family":"Peverelli","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytad496","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,10]]},"article-number":"ytad496"}}